TARRYTOWN, N.Y., Sept. 5, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX ) chief executive officer Mark R. Baker will make a presentation on Thursday, September 12 at 1:30 PM EDT at the Stifel Healthcare Conference in Boston. The company overview will be webcast live via a link on the Events page of Progenics' website and archived there for 30 days.
About Progenics
Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in late-stage clinical development. Progenics' first-in-class PSMA targeted technology platform includes an antibody drug conjugate therapeutic and a small molecule targeted imaging agent, both in Phase 2 clinical trials. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra TM , an ultra-orphan radiotherapy candidate also in phase 2 under an SPA. Progenics' first commercial product, Relistor ® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc. Ono Pharmaceutical Co. is developing Relistor in Japan. For additional information, please visit www.progenics.com .
Additional information concerning Progenics and its business may be available in press releases or other announcements and public filings made after this announcement.
(PGNX-G)
Kathleen Fredriksen Corporate Development (914) 789-2871